1. Home
  2. SCYX vs KTCC Comparison

SCYX vs KTCC Comparison

Compare SCYX & KTCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • KTCC
  • Stock Information
  • Founded
  • SCYX 1999
  • KTCC 1969
  • Country
  • SCYX United States
  • KTCC United States
  • Employees
  • SCYX N/A
  • KTCC N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • KTCC Electrical Products
  • Sector
  • SCYX Health Care
  • KTCC Technology
  • Exchange
  • SCYX Nasdaq
  • KTCC Nasdaq
  • Market Cap
  • SCYX 40.9M
  • KTCC 34.0M
  • IPO Year
  • SCYX 2014
  • KTCC N/A
  • Fundamental
  • Price
  • SCYX $0.90
  • KTCC $2.39
  • Analyst Decision
  • SCYX
  • KTCC
  • Analyst Count
  • SCYX 0
  • KTCC 0
  • Target Price
  • SCYX N/A
  • KTCC N/A
  • AVG Volume (30 Days)
  • SCYX 94.5K
  • KTCC 25.2K
  • Earning Date
  • SCYX 05-07-2025
  • KTCC 05-06-2025
  • Dividend Yield
  • SCYX N/A
  • KTCC N/A
  • EPS Growth
  • SCYX N/A
  • KTCC N/A
  • EPS
  • SCYX N/A
  • KTCC N/A
  • Revenue
  • SCYX $3,746,000.00
  • KTCC $514,394,000.00
  • Revenue This Year
  • SCYX $460.12
  • KTCC N/A
  • Revenue Next Year
  • SCYX $253.87
  • KTCC N/A
  • P/E Ratio
  • SCYX N/A
  • KTCC N/A
  • Revenue Growth
  • SCYX N/A
  • KTCC N/A
  • 52 Week Low
  • SCYX $0.73
  • KTCC $2.21
  • 52 Week High
  • SCYX $3.07
  • KTCC $6.14
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 45.97
  • KTCC 39.50
  • Support Level
  • SCYX $0.89
  • KTCC $2.25
  • Resistance Level
  • SCYX $0.99
  • KTCC $2.40
  • Average True Range (ATR)
  • SCYX 0.08
  • KTCC 0.13
  • MACD
  • SCYX 0.01
  • KTCC 0.01
  • Stochastic Oscillator
  • SCYX 64.71
  • KTCC 36.73

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About KTCC Key Tronic Corporation

Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.

Share on Social Networks: